Livogiva
Teriparatide biosimilar developed by Not stated in the EMA table. Reference product Forsteo (Forteo in the United States).
Brands by market: Livogiva (EU); Qutavina (EU, withdrawn) · Commercial partner or holder: Theramex (Livogiva); EuroGenerics (Qutavina)
FDANot listed
EMAAug 2020authorised
MHRANot listed
PMDANot listed
HCNot listed
CDSCONot listed
EDENot listed
Approved or registered in 1 of 7 markets
Connections
About Livogiva
Livogiva is a teriparatide sold in Europe by Theramex, approved in August 2020. A duplicate under the name Qutavina, held by EuroGenerics, was approved on the same day and withdrawn within months. The developer is not named in the European record.
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union · Livogiva
European Medicines Agency and European CommissionApprovedBrand
Livogiva
Holder or applicant
Theramex Ireland Limited
Pathway
Centralised (Article 10(4))
Approved
Aug 2020
Application or permission
EMEA/H/C/005087
Presentations
see SmPC
Source
S017 (EMA) · checked Sep 2026
EMA
European Union · Qutavina
European Medicines Agency and European CommissionWithdrawnBrand
Qutavina
Holder or applicant
EuroGenerics Holdings B.V.
Pathway
Centralised (Article 10(4))
Approved
Aug 2020
Application or permission
EMEA/H/C/005388
Withdrawn
Nov 2020
Presentations
see SmPC
Remarks
Duplicate authorisation, withdrawn within three months.
Source
S017 (EMA) · checked Sep 2026
MHRA
United Kingdom
Not listed by MHRA.
PMDA
Japan
Not listed by PMDA.
HC
Canada
Not listed by HC.
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Livogiva holds an approval, these are the other teriparatide biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| EMA | 4 | CinnaGen (Zandoriah), Gedeon Richter (Terrosa / Movymia), Intas Pharmaceuticals (Sondelbay / Intas teriparatide), Strides Pharma (Kauliv) |
Chronology
- EMAAug 2020Authorised by the European Commission as Livogiva
- EMANov 2020Qutavina authorisation withdrawn
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)
Planning teriparatide biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.